MAJIC: A Phase III Trial of Acalabrutinib + Venetoclax versus Venetoclax + Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaChristine E. Ryan, Lindsey E. Roeker, Hasan Alhasani et al.|Future Oncology|2022Cited by 35
Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysisMatthew S. Davids, Véronique Leblond, Catherine Waweru et al.|Clinical Therapeutics|2020Cited by 24
Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemiaMatthew S. Davids, Ingo Ringshausen, Catherine Waweru et al.|Leukemia & lymphoma/Leukemia and lymphoma|2021Cited by 16